Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
A dopamine agonist is a medicine that activates one or more dopamine receptors. It can imitate some effects of dopamine without first being converted into dopamine in the body. Dopamine agonists differ in which receptor subtypes they affect, how long they act, and how they are administered. Common examples include pramipexole, ropinirole, rotigotine, apomorphine, bromocriptine, and cabergoline.
read more about dopamine agonist ...Dopamine agonists are used to treat motor symptoms of Parkinson disease, either alone or with levodopa. Selected agents are also used for restless legs syndrome, high prolactin levels, and related endocrine conditions. Apomorphine products can treat sudden off episodes in some people with Parkinson disease. The appropriate drug depends on the condition, age, symptom pattern, other medicines, and risk of adverse effects.
Dopamine agonists bind directly to dopamine receptors and activate signaling in the brain or other tissues. In Parkinson disease, stimulation of dopamine pathways involved in movement can reduce slowness, stiffness, and other motor symptoms. In hyperprolactinemia, dopamine-receptor activation can reduce prolactin release from the pituitary gland. The clinical effect depends on the receptor profile, dose, and area of the body reached by the medicine.
Dopamine agonists are commonly grouped as ergoline or non-ergoline medicines. Non-ergoline agents include pramipexole, ropinirole, rotigotine, and apomorphine and are widely used for neurological conditions. Ergoline agents include bromocriptine and cabergoline and are commonly used for prolactin-related disorders. Products are available as tablets, extended-release tablets, skin patches, injections, and sublingual films.
Common effects include nausea, dizziness, low blood pressure when standing, sleepiness, swelling, hallucinations, and confusion. Some patients develop impulse-control problems involving gambling, shopping, eating, or sexual behavior. Sudden sleep episodes can create serious driving and workplace risks. Treatment should usually be reduced gradually because abrupt discontinuation can cause withdrawal symptoms or severe worsening of Parkinson-related symptoms.
No. Levodopa is a precursor that the body converts into dopamine, while dopamine agonists stimulate dopamine receptors directly. The medicines can be used together in Parkinson disease.
Yes. Some patients develop new or intensified urges involving gambling, spending, eating, or sexual activity. These changes should be reported promptly because dose adjustment or a treatment change can be needed.
Yes. Severe sleepiness or sudden sleep episodes can occur, sometimes without clear warning. Patients should avoid driving or hazardous tasks when affected.
It generally should not be stopped abruptly without medical guidance. Gradual dose reduction can lower the risk of withdrawal symptoms and severe symptom worsening.
Dopamine Agonists. StatPearls (NCBI Bookshelf). https://www.ncbi.nlm.nih.gov/books/NBK551686/. Date Accessed August 6, 2026.
Pramipexole Dihydrochloride Tablets: Prescribing Information. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f4d97c2e-f447-4cfe-b9d4-852323f0cfb5. Date Accessed August 6, 2026.
Ropinirole Tablets: Prescribing Information. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=16752e1b-10eb-4c31-92d4-ff6c6e8466f4. Date Accessed August 6, 2026.
APOKYN (Apomorphine Hydrochloride Injection): Prescribing Information. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3235535d-9ef9-4657-8b2a-176a807d091c. Date Accessed August 6, 2026.
Cabergoline Tablets: Prescribing Information. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=57cbd81e-fdb9-4060-80ee-6e8581c463a4. Date Accessed August 6, 2026.